Currently Viewing:
ACCC Annual Meeting & Cancer Center Business Summit
Dr Allen Lichter: Technology Is Present in Oncology, but the Future Is Brighter
March 21, 2019
Envisioning the Future of Cancer Care
March 21, 2019
Joe Flower on Rethinking the Way We Address Cancer Care Delivery
March 21, 2019
Different Vantage Points, but Similar Goals of High-Value Care, Patient Satisfaction
March 22, 2019
Dr John Halamka Outlines Trends in Digital Health
March 22, 2019
Feyi Olopade Ayodele Highlights How CancerIQ Helps With Genetic Testing
March 22, 2019
Ben Jones Outlines Policies Having the Biggest Impact on Cancer Care Delivery
March 23, 2019
Erich Mounce Discusses How Community Oncology Can Address Inequalities in Cancer Care
March 23, 2019
Digital Health Lessons From Around the World
March 24, 2019
Dr Ali McBride Discusses the Role of Biosimilars in Oncology
March 25, 2019
Ben Jones Explains Reimbursement Challenges Facing Community Oncologists
April 04, 2019
Alexandra Quinn on the Importance of Sustaining the Role of Community Health Workers in Cancer Care
April 08, 2019
Erich Mounce Discusses How Technology Needs to Evolve to Help Oncologists Deliver Care
April 08, 2019
Ben Jones Weighs the Implications of Site-Neutral Payments
May 24, 2019
Erich Mounce Emphasizes the Importance of Palliative Care
June 01, 2019
Currently Reading
Ben Jones Discusses the Impact of Step Therapy in Medicare Advantage
June 07, 2019
Ben Jones: Oncologists Still Face Challenges When Trying to Extract Data From EHRs
June 19, 2019

Ben Jones Discusses the Impact of Step Therapy in Medicare Advantage

This is probably the biggest concern that every community and cancer practice should be looking at, explained Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health.


This is probably the biggest concern that every community and cancer practice should be looking at, explained Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health.

Transcript

CMS has proposed allowing step therapy in Medicare Advantage plans for Part B drugs. How do you think this will impact cancer patients?

This is probably the biggest concern that every community and cancer practice should be looking at. The president has come out with a number of proposals included in the drug pricing blueprint that have a specific impact on Part B drugs. The secretary made it clear when the drug pricing proposal was released that his desire was to, as much as his ability allows, move Part B drugs into Part D. In absent the ability to kind of make an easy shift into Part D, what he wants to do is mimic some of the characteristics that Part D has in the Part B space. That’s why you’re seeing such quick action on step therapy, on a relaxing of the protected classes, and on a number of utilization management tools that are likely to come down the pipe.

I do think that this is something that has the biggest potential to threaten access to care for cancer patients across the country. These are just 2 examples. Step therapy and protected classes have already been finalized. The changes to both of those proposals have been finalized in Medicare Advantage, but we’ve also got another proposal with the International Pricing Index that again has the potential to insert a new third-party vendor into the drug supply chain, impacting access to patient timely care and potentially a new round of utilization management tools.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up